Compare Intuit Inc. (INTU) vs BIO-TECHNE Corp (TECH) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Intuit Inc. vs BIO-TECHNE Corp — how do they compare? Intuit Inc. trades at $337.02 (market cap $91.48B), while BIO-TECHNE Corp trades at $72.13 (market cap $11.24B). The key difference: Intuit Inc. is far larger — about 8.1× BIO-TECHNE Corp's market cap, and Intuit Inc. pays the higher dividend (1.44%). Which is the better fit depends on your goals.
| INTU | TECH | |
|---|---|---|
Market Cap | $91.48B | $11.24B |
Sector | Technology | Health |
52-Week High | $717.21 | $72.29 |
52-Week Low | $255.07 | $43.31 |
Enterprise Value | $89.94B | $11.32B |
Dividend Yield | 1.44% | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Intuit (INTU) trades at $325.25, up 1.04% today, with a bullish technical signal from moving averages and oscillators. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $12.8 exceeding expectations. Revenue grew to $18.83 billion in 2025, and net income margin improved to 20.54%. However, the stock faces headwinds from multiple law firm investigations into securities fraud allegations related to pricing issues, contributing to a significant decline from its 52-week high.
The outlook for Intuit is mixed; strong fundamentals and a consensus price target of $401.00 suggest upside potential, but legal risks and negative sentiment from recent downgrades pose near-term challenges. Investors should weigh the company's robust profitability and AI-driven growth against regulatory scrutiny and competitive pressures in the fintech software market.
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Intuit Inc.
Intuit is a provider of small-business accounting software (QuickBooks), personal tax solutions (TurboTax), and professional tax offerings (Lacerte). Founded in the mid-1980s, Intuit controls the majority of U.S. market share for small-business accounting and DIY tax-filing software.
Read more on INTU →About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →
